This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Sancuso-product-image
sancuso-patch

SANCUSO®

granisetron transdermal patch

SANCUSO transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemotherapy in adult patients with swallowing difficulties.1

Click here for prescribing information and adverse event reporting.

Nausea and vomiting is a common side-effect of chemotherapy. Beween 30% - 90% of patients receiving highly emetogenic (HEC) or moderately emetogenic (MEC) chemotherapy experience some form of chemotherapy-induced nausea and vomiting (CINV).2,3

SANCUSO transdermal patch is designed to prevent nausea and vomiting in patients treated with both highly emetogenic (HEC) and moderately emetogenic (MEC) chemotherapy agents.1

Pharmacotherapy

SANCUSO®

  • INTRODUCTION

    Find out about SANCUSO, the first and only 5-HT3 antagonist patch for the treatment of CINV.4

  • EFFICACY

    Evidence from clinical studies demonstrating the efficacy of SANCUSO in relieving CINV in patients receiving chemotherapy.

  • TOLERABILITY

    Guidance on the most commonly reported side effects and adverse drug reactions.1

  • PRESCRIBING SANCUSO

    Guidance on how to prescribe SANCUSO.

  • RESOURCES

    Information and resources for the management of patients who have been prescribed SANCUSO.

  • PRESCRIBING INFORMATION

    Direction on prescribing SANCUSO covering information from dosage ranges to precautions.

Average:

  • References

    1. SANCUSO 3.1 mg/24 hours transdermal patch SPC.

    2. Aapro M, et al. Annals of Oncology. 2012;23(8):1986–92.

    3. Grunberg SM & Ireland A. Advanced Studies in Nursing. 2005;3:9–15.

    4. eMIMS. June 2021.

    KKI/UK/IM-M1/0001 November 2023